The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAilsynBio and Dong-E-E-Jiao have officially signed a cooperation agreement to launch an innovative project aimed at transforming the traditional medicine landscape. The partnership focuses on integrating advanced Artificial Intelligence (AI) technologies into the research and development of Traditional Chinese Medicine (TCM). By leveraging AilsynBio's AI-driven drug discovery platform, the collaboration seeks to accelerate the identification of active compounds and enhance product efficacy. Dong-E-E-Jiao aims to modernize its product pipeline and drive innovation within the broader health industry through this digital transformation. Analysts view this move as a strategic step toward combining ancient medical wisdom with cutting-edge computational science. The initiative is expected to strengthen Dong-E-E-Jiao's competitive position in the biotech sector over the long term.